- All
- Event Participitation (6)
- News & Press releases (6)
- Scientific Publication (3)
Scientific Publication
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Editor’s summary Relapse of acute myeloid leukemia (AML) is driven by populations of leukemic stem or progenitor cells (LSCs), which are resistant to chemotherapy. Here,...
News & Press releases
Cycuria Publishes Groundbreaking Research in Science Translational Medicine Demonstrating Lymphotoxin Alpha Eradicates Acute Myeloid Leukemia
The study, led by Cycuria’s scientific founder, Prof. Dr. Philipp Jost , a clinician-scientist, and his research team, describes a natural tumor-suppressing mechanism mediated by...
Event Participitation
Cycuria’s CEO, Dr. Nisit Khandelwal, to Present at the Upcoming BIO-Europe Conference in Vienna
Join our CEO as he presents Cycuria Therapeutics‘ latest advancements in oncology innovation at the upcoming BIO-Europe conference in Vienna . 📍 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗩𝗶𝗲𝗻𝗻𝗮 🗓️...
Event Participitation
Cycuria Founder, Univ.-Prof. Dr. med. Philipp Jost, joins the Scientific Panel at the Biotech Summit Austria
🧬 𝗣𝗮𝗻𝗲𝗹: “Science With Purpose – Bold Biotech in Uncertain Times” 📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟯–𝟮𝟰, 𝟮𝟬𝟮𝟱 📍 Great value for money This session will bring together...
News & Press releases
Interview with our CEO featured by ABA – INVEST in AUSTRIA!
We’re pleased to share an exclusive interview with our CEO featured by ABA – INVEST in AUSTRIA ! In this article, we talk about Cycuria...
News & Press releases
Cycuria Therapeutics Announces the Formation of a Distinguished Advisory Board and Significant Public Grant Funding from FFG and AWS
We’re proud to unveil exciting news from Cycuria Therapeutics. We’ve secured grant funding from two leading Austrian national bodies, FFG and AWS, and today announce...